Glial Activating Compounds for NEC via BDNF Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Necrotizing enterocolitis (NEC) in premature infants is a leading cause of death with no specific treatment, and the underlying mechanisms and strategies to reverse the heightened inflammatory response are not fully understood, particularly regarding TLR4 signaling and enteric glia function.
Innovation Solution
The use of glial activating compounds that induce brain-derived neurotrophic factor (BDNF) release from enteric glia to restrain TLR4 signaling, along with TLR4 antagonists, antioxidants, and glial agonists to prevent or treat NEC by attenuating enteric glia loss and reducing inflammation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If TLR4 signaling is activated in the intestinal epithelium of premature infants, then bacterial colonization response is enhanced, but inflammatory response becomes exuberant leading to NEC
Solution Approach 1:
The patent introduces enteric glia as an intermediary cell type that mediates between bacterial colonization and the inflammatory response. Enteric glia release BDNF to restrain TLR4 signaling in the intestinal epithelium, thereby dampening the excessive inflammatory response while maintaining necessary bacterial recognition. This intermediary mechanism prevents NEC by regulating the signaling pathway without completely abolishing bacterial detection capability.
Solution Approach 2:
The patent employs glial activating compounds that induce BDNF release from enteric glia, changing the biochemical parameter of TLR4 signaling activity. By modulating the level of TLR4 signaling through BDNF-mediated restraint, the system achieves a balanced state where bacterial response is maintained but excessive inflammation is prevented. This parameter change approach transforms the pathological hyper-responsive state into a protective regulated state.
2Productivity
If enteric glia are deficient in premature bowel, then intestinal development is impaired, but TLR4 signaling becomes unrestrained leading to NEC
Solution Approach 1:
The patent employs glial activating compounds that stimulate enteric glia to release BDNF in advance, creating a protective restraint on TLR4 signaling before bacterial colonization triggers excessive inflammation. This preliminary action ensures that even in premature infants with deficient enteric glia, the glial cells are activated early to establish TLR4 regulation, preventing NEC while supporting intestinal development.
Solution Approach 2:
The patent utilizes the inherent capability of enteric glia to release BDNF as a self-protective mechanism. By providing glial activating compounds, the system enables enteric glia to self-regulate TLR4 signaling in the intestinal epithelium. This self-service approach allows the premature intestine to autonomously restrain excessive inflammation through its own glial cells, rather than requiring external intervention for every inflammatory challenge.
3Reliability
If glial activating compounds are administered, then BDNF release from enteric glia is induced, but compound specificity and safety profile must be optimized
Solution Approach 1:
The patent identifies and characterizes glial activating compounds with specific molecular structures and properties that induce BDNF release. By optimizing compound parameters such as molecular weight, functional groups, and structural features, the invention achieves reliable BDNF induction while maintaining appropriate specificity. The identification of compounds like oxolinic acid and its analogs demonstrates how parameter optimization balances efficacy with safety profile.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
These approaches effectively prevent or treat NEC by reducing TLR4 signaling and inflammation in both animal models and human tissues, offering a novel therapeutic strategy for NEC and related conditions like irritable bowel syndrome and inflammatory bowel disease.
Implementation Method 1
the enteric glia, which are relatively deficient in the premature bowel, serve to restrain TLR4 signaling in the intestinal epithelium through the release of the peptide brain-derived neurotrophic factor (BDNF)
Implementation Method 2
the inventors have now identified a novel class of so-named 'glial activating compounds' that induce BDNF release from the enteric glia, and which prevented NEC in mice through reduced TLR4 signaling
Data Source
AI summary
The present inventive concepts, compositions and methods are show that the enteric glial serve to restrain the exaggerated TLR4 signaling that occurs in the premature intestinal epithelium via the release of BDNF, and that necrotizing enterocolitis (NEC) develops due to a loss of enteric glia. Compositions and methods of treatment of NEC and related enteric disease in prenatal, premature and neonatal subjects using compositions heretofore unknown for inhibition of NEC or activation of enteric glia are also provided.